Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results

Background: Anti-HER2 agents were a breakthrough in the treatment of HER2-enriched breast cancer (BC). In this study, we aimed to describe the real-life efficacy and safety of pertuzumab-trastuzumab-taxane (PTT) combination in BC patients. Methods: This study was conducted by the Turkish Oncology Group and reached 35 centers nationwide. 309 visceral metastatic, and trastuzumab naive patients who received first line PTT were included. Results:...